Real-world use of pemigatinib for the treatment of cholangiocarcinoma in the US.

ABSTRACT:

Background

Pemigatinib demonstrated efficacy in fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA) in the FIGHT-202 trial. However, limited real-world evidence exists on treatment patterns and outcomes in this setting.

Patients and methods

Patient characteristics, treatment patterns, and outcomes of US adults who received pemigatinib for unresectable, locally advanced or metastatic CCA were collected via retrospective physician-abstracted chart review. Results were summarized using descriptive statistics.

Results

Data from 120 patients (49.2% male; 55.0% White; 19.2% Hispanic; median age at initial pemigatinib prescription, 64.5 years) were collected from 18 physicians/practices. At the time of prescribing, 90.0% of patients had metastatic disea

SUBMITTER: Saverno K 

PROVIDER: S-EPMC11783287 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature